在里斯本這座面朝大洋，向海而生的港口城市，連接與交流始終是其鮮明特質(zhì)。

伊比利亞半島第一長河塔霍河于此處入海，也為這里帶來了開放的視野與流動的格局，讓不同創(chuàng)新想法在此匯聚、連接、交融。

如今，在全球生物醫(yī)藥產(chǎn)業(yè)，這種“連接”有了新的意義。

在BIO-Europe Spring 2026期間，藥明康德如約在里斯本舉辦“藥明之夜”。近300位來自歐洲乃至全球的創(chuàng)業(yè)家、投資者、領(lǐng)軍人齊聚一堂。在繁忙的日常之外，嘉賓們得以回望過往的發(fā)展歷程，思考驅(qū)動行業(yè)前行的根本動力，并在交流中汲取新的啟發(fā)。藥明康德也借此契機(jī)，對長期以來為行業(yè)發(fā)展作出的探索與貢獻(xiàn)的創(chuàng)新者表達(dá)由衷的敬意。

韌性為基，合作共筑創(chuàng)新

在活動現(xiàn)場，來自北歐、德國、法國和比利時多家投資機(jī)構(gòu)的資深專家從產(chǎn)業(yè)韌性、合作共贏以及加速創(chuàng)新等多個維度，分享了對生物科技領(lǐng)域發(fā)展前景的樂觀判斷。

Eir Ventures創(chuàng)始合伙人Stephan Christgau博士指出，生物醫(yī)藥的長期韌性深植于產(chǎn)業(yè)根基之中：“新藥研發(fā)的需求始終存在，未被滿足的臨床需求依然巨大，創(chuàng)新也在持續(xù)發(fā)生。我們在看到挑戰(zhàn)的同時，更要看到希望。”

“這個行業(yè)的根基，是一群始終不輕言放棄的人。”TVM Capital Life Science管理合伙人Hubert Birner博士進(jìn)一步強(qiáng)調(diào)，產(chǎn)業(yè)韌性的背后，協(xié)同合作始終發(fā)揮著關(guān)鍵作用：“行業(yè)經(jīng)歷過起伏，也經(jīng)歷過復(fù)蘇，但始終不變的是創(chuàng)業(yè)家、投資者、服務(wù)平臺與醫(yī)藥企業(yè)之間的合作。這種協(xié)同精神，需要被持續(xù)傳承。”

V-Bio Ventures聯(lián)合創(chuàng)始人兼管理合伙人Willem Broekaert博士則以“餐桌”來比喻合作共贏的行業(yè)生態(tài)：“幾十年前，參與者還很少，而如今越來越多‘賓客’加入。參與者增加，也帶來了更豐富的資源與合作機(jī)會。關(guān)鍵在于共享、合作，并從彼此的經(jīng)驗與方法中學(xué)習(xí)。”

Jeito Capital首席科學(xué)官Claudio Costa-Neto博士則回歸產(chǎn)業(yè)本質(zhì)，強(qiáng)調(diào)為患者加速創(chuàng)新：“以患者為中心，意味著加快研發(fā)節(jié)奏，讓療法能及時到達(dá)患者手中。這需要資金，也需要團(tuán)隊、能力，以及貫穿整個價值鏈的協(xié)作。”

自成立以來，藥明康德協(xié)助客戶更早識別挑戰(zhàn)、更好地連接能力與技術(shù)、也更快地用“藥明速度”讓產(chǎn)業(yè)充滿韌性，讓創(chuàng)新穩(wěn)步向前。

動能為勢，驅(qū)動創(chuàng)新加速

如果說“韌性”構(gòu)成了行業(yè)的底色，那么當(dāng)下積累的發(fā)展動能，正引領(lǐng)行業(yè)邁向新的階段。

在全球產(chǎn)業(yè)生態(tài)圈，歐洲以其深厚而扎實的科研基礎(chǔ)聞名。沒有人質(zhì)疑這些科學(xué)的含金量，關(guān)鍵在于，如何將這些科研成果更快轉(zhuǎn)化為創(chuàng)新療法。

令人振奮的是，新一代生物科技公司正不斷涌現(xiàn)，站在推動創(chuàng)新轉(zhuǎn)化的前沿。

“藥明之夜”本身就是最好的注腳——現(xiàn)場近300位嘉賓所代表的創(chuàng)新公司，20多家在過去半年剛剛完成融資。

比如FoRx Therapeutics在A輪融資中獲得5000萬美元，開發(fā)治療癌癥的PARG抑制劑；Aerska先后獲得6000萬美元，推進(jìn)中樞神經(jīng)系統(tǒng)RNA療法；MRM Health則獲得5500萬美元助力，研發(fā)治療炎癥疾病的微生物組療法。

盡管技術(shù)路徑和疾病領(lǐng)域各有不同，但有一點(diǎn)是相通的——這些近期的融資事件，共同反映出創(chuàng)新管線的持續(xù)涌現(xiàn)，行業(yè)活力不斷增強(qiáng)。

當(dāng)科學(xué)、資本與合作形成有效連接，當(dāng)產(chǎn)業(yè)鏈各環(huán)節(jié)逐步協(xié)同，行業(yè)發(fā)展的動能也隨之增強(qiáng)。

這些，最終將轉(zhuǎn)化為造福患者的療法。

平臺為橋，加速創(chuàng)新落地

在行業(yè)韌性與發(fā)展勢頭之外，如何實現(xiàn)高效落地，成為推動創(chuàng)新轉(zhuǎn)化的關(guān)鍵。

秉承“讓天下沒有難做的藥、難治的病”的愿景，藥明康德在過去二十余年間持續(xù)打造端到端的一體化CRDMO平臺。

目標(biāo)始終明確：讓創(chuàng)新走得更快，也更穩(wěn)。

“我們共同見證了生物科技領(lǐng)域的發(fā)展。”藥明康德副總裁Dave Madge博士表示，“我們很榮幸能夠參與其中，支持從早期研發(fā)到商業(yè)化生產(chǎn)的各個階段。”

隨著越來越多歐洲企業(yè)進(jìn)入臨床及商業(yè)化階段，近距離賦能創(chuàng)新者的重要性日益凸顯。

藥明康德已在歐洲深耕多年，2016年，位于德國慕尼黑的新藥發(fā)現(xiàn)服務(wù)公司Crelux成為藥明康德子公司。十年來，慕尼黑基地員工數(shù)已經(jīng)從最初的幾十人擴(kuò)增到超過百人。

大約5年前，瑞士庫威基地成為藥明康德CRDMO網(wǎng)絡(luò)的一員，為歐洲及全球客戶提供高質(zhì)量制劑生產(chǎn)服務(wù)。持續(xù)的能力規(guī)模建設(shè)，讓基地的口服劑型包裝產(chǎn)能已于2024年翻倍，噴霧干燥車間預(yù)計將于2026年第四季度投入運(yùn)營。

去年，藥明康德宣布將在慕尼黑設(shè)立歐洲總部，更好地支持位于歐洲的客戶。

藥明康德旗下Crelux公司負(fù)責(zé)人Thomas Meins博士表示：“我們在10年前加入藥明康德。此后，一直在建設(shè)貼近歐洲客戶的研發(fā)與供應(yīng)體系。隨著項目推進(jìn)，本地團(tuán)隊能夠支持研究與生產(chǎn)各個環(huán)節(jié)。”

當(dāng)項目推進(jìn)更高效，協(xié)同更順暢，創(chuàng)新就能更快走向下一階段，也離患者更進(jìn)一步。

協(xié)同為力，推動創(chuàng)新發(fā)生

如果韌性支撐行業(yè)發(fā)展，發(fā)展動能推動行業(yè)前行，而合作則讓這一切成為可能。

藥明康德副總裁、“藥明之夜”主席蔡輝博士表示：“幾個小時前，藥明康德發(fā)布了年報，2025年業(yè)績再創(chuàng)歷史新高，這既得益于CRDMO業(yè)務(wù)模式的獨(dú)特優(yōu)勢，也體現(xiàn)了全球團(tuán)隊優(yōu)秀的管理執(zhí)行能力，更是來自全球所有合作伙伴的支持。”

她進(jìn)一步強(qiáng)調(diào)：“更重要的是，我們所做的一切，都是在幫助創(chuàng)新療法更快觸達(dá)患者。”

“行業(yè)的進(jìn)步不總是一帆風(fēng)順，但總是在協(xié)同合作中不斷向前。”

蔡輝博士總結(jié)道：“我們已經(jīng)見證了多次起伏，但有一點(diǎn)始終不變：保持韌性，保持樂觀。”

當(dāng)夜色降臨塔霍河畔，這場關(guān)于科學(xué)、資本與合作的對話并未結(jié)束。

它正在以另一種方式延續(xù)，在新的合作中，在推進(jìn)中的項目里，在下一次臨床突破的節(jié)點(diǎn)上。

連接不會停留在一場活動，合作也不止于一時相聚。

當(dāng)越來越多想法在這里被點(diǎn)亮、被帶走、再落地為現(xiàn)實，創(chuàng)新便不再只是討論的話題，而成為正在發(fā)生的進(jìn)程。

而所有這些努力，終將匯聚成一個共同的方向——更快抵達(dá)患者。

WuXi Night in Lisbon: A Spirit of Connection Shapes Biotech’s Next Chapter

For centuries, Lisbon stood as a point of departure. Against the backdrop of the Tagus River, ships and ideas traveled outward across the ocean, connecting distant parts of the world.

This week, that same spirit of connection felt just as relevant across the global life sciences ecosystem.Alongside BIO-Europe Spring 2026, WuXi AppTec hosted WuXi Night in Lisbon, bringing together biotech entrepreneurs, investors, and pharmaceutical leaders from across Europe and beyond.

The gathering continues a tradition: creating a space to look beyond day-to-day operations, offering a moment to reflect on why we are here and what drives our work, and drawing inspiration from one another.At its core, it reflects a shared purpose across the industry: Advancing Breakthroughs For Patients.

An Industry That Endures

At WuXi Night in Lisbon, four experienced investors reinforced an optimistic outlook for biotech.

Dr. Stephan Christgau, Founding Partner of Eir Ventures, highlighted the resilience embedded in the sector. “There is still a fundamental need to develop new drugs. There’s a lot of unmet medical need, and innovation continues,” he said. “It’s easy to focus on the dark clouds, but we should also look at the silver lining.”

“This community is defined by people who don’t give up,” said Dr. Hubert Birner, Managing Partner of TVM Capital Life Science, echoing a message of resilience. “Over the years, we’ve seen downturns and recoveries.What stands out is the collaboration between entrepreneurs, investors, service providers, and pharma. That spirit is what we need to keep alive.”

Dr. Willem Broekaert, Co-Founder and Managing Partner of V-Bio Ventures, offered a metaphor capturing the essence of global collaboration. “Think of our industry as a dinner table,” he said. “Decades ago, there were only a few guests. Today, many more have joined.” While some may worry about a smaller share of the “meal,” he offered a different perspective: “More guests also bring more food. The opportunity is to share, to collaborate, and to learn from each other’s ‘cuisine.’”

Dr. Claudio Costa-Neto, Chief Scientific Officer of Jeito Capital, brought the discussion back to patients. “Being patient-driven means accelerating development so therapies reach people in time,” he said. “That requires capital, but also the right catalysts—teams, expertise, and collaboration across the value chain.”

Through the ability to anticipate challenges, integrate capabilities, and accelerate the path from idea to execution,WuXi AppTec helps build resilience with “WuXi Speed”, even in the most demanding environments.

A Convergence of Momentum

If the first theme of the evening was resilience, the second was momentum.

Europe has excellent science. The challenge is to match that with execution and investment, so the industry can translate it into medicines as quickly as possible.

Grounded in Europe’s scientific strength and increasingly supported by renewed capital, industry leaders pointed to a new generation of companies advancing under tighter conditions, where discipline and creativity are becoming defining traits.

That shift was visible in the room.Among nearly 300 guests attending WuXi Night in Lisbon, many represented companies at the forefront of innovation that had secured financing in the past six months.FoRx Therapeutics raised $50 million to develop PARG inhibitors for cancer; Aerska secured $60 million to advance RNA medicines for CNS diseases; MRM Health raised $55 million to progress microbiome-based therapeutics for inflammatory conditions…

These companies span diverse modalities and disease areas, reflecting a gradual return of investor confidence and a growing pipeline of innovation. It also captured a broader dynamic echoed throughout the evening:when science, capital, and partnership converge, when different segments connect, and when established players shake hands, momentum follows.

Enabling Through Integrated Platform

If resilience defines the industry and momentum signals its direction, the next question becomes execution: how to translate science and capital into medicines at speed.

Guided by its vision that “every drug can be made, and every disease can be treated,” WuXi AppTec has spent more than two decades building an end-to-end platform to support that transition: evolving from a single laboratory into a global network spanning Asia, Europe, and North America, and from early chemistry services into an integrated CRDMO platform that connects Research, Development, and Manufacturing.The company’s growth reflects a single focus: enabling innovation to move forward, with speed, scale, and greater certainty.

“We’ve all seen the growth of biotech,” said Dr. Dave Madge, VP of WuXi AppTec. “From early academic discoveries to venture-backed startups and established pharma, all of those strategies are represented here.And we’re very grateful to work with you across the whole landscape—from early discovery through to commercial manufacturing.”

As more European companies advance into development, the need for local capabilities has become increasingly clear.

WuXi AppTec has invested in Europe for many years. In 2016, Crelux, a drug discovery services company based in Munich, Germany, became a subsidiary of WuXi AppTec. Over the past decade, the Munich site has grown from just a few dozen employees to more than one hundred.

Approximately five years ago, the Couvet site in Switzerland became part of WuXi AppTec’s CRDMO network, providing high-quality drug product manufacturing services to customers in Europe and around the world. Through continued capacity expansion, the site’s oral dosage form packaging capacity doubled in 2024, and a new spray drying facility is expected to become operational in the fourth quarter of 2026.

Last year,WuXi AppTec announced that Munich will serve as the company’s European headquarters to better support hundreds of customers in Europe.

Dr. Thomas Meins, Managing Director at Crelux, a WuXi AppTec company in Munich, pointed to the company’s long-term commitment to Europe. “We joined WuXi AppTec 10 years ago. Since then, we have been building a research and supply chain that is close to European companies,” he said. “As programs progress, you will find qualified teams in Europe to support studies and manufacturing locally.”

This approach reflects WuXi AppTec’s role in the ecosystem: integrating global platforms with localized delivery, enabling companies to scale efficiently and without fragmentation.

Progress, Together

If one message carried through the evening in Lisbon, it was this:resilience sustains the industry, momentum moves it forward, and collaboration makes progress possible.

For Dr. Hui Cai, VP of WuXi AppTec and host of WuXi Night, that progress is best understood through partnership. “Just this morning, we reported record financial results. In 2025, WuXi AppTec achieved record performance with strong growth, demonstrating the strength of our unique CRDMO business model and the exceptional execution of our global team.” she said. “We’re deeply grateful for everyone’s support—that’s what made us where we are today.”

More importantly, she added, “every service we provide, every success we achieve means we are helping to bring medicines closer to patients.That reflects not only the strength of our platform, but the trust and collaboration from all of you.”

“Progress is never a straight line. It can only be made collectively.” Hui concluded, “We have seen the industry go through many ups and downs, but one thing always holds true: stay persistent, and stay optimistic.”

That sense of shared achievement and shared responsibility echoed across the room.In a year shaped by both challenges and recovery, the industry continues to adapt, to persevere, and to move forward—together.

免責(zé)聲明：本文 僅作信息交流之目的，文中觀點(diǎn)不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點(diǎn)。本文也不是治療方案推薦。如需獲得治療 方案指導(dǎo)，請前往正規(guī)醫(yī)院就診。

版權(quán)說明：歡迎個人轉(zhuǎn)發(fā)至朋友圈，謝絕媒體或機(jī)構(gòu)未經(jīng)授權(quán)以任何形式轉(zhuǎn)載至其他平臺。轉(zhuǎn)載授權(quán)請在「藥明康德」微信公眾號回復(fù)“轉(zhuǎn)載”，獲取轉(zhuǎn)載須知。